Polypeptides with good safety, in vivo degradability and structural versatility are considered as one of the most promising materials for drug and gene delivery. However, in spite of great scientific progress made in the past decade, few nanomedicines self-assembled from polypeptides have been translated into the clinical trials, partly due to complex fabrication or suboptimal therapeutic outcomes. Based on a novel polylipopeptide, poly(α-aminopalmitic acid), we have developed a series of robust nanovehicles including micelles, polymersomes, and chimaeric polymersomes that have shown to efficiently load and deliver chemotherapeutics and biotherapeutics (e.g. doxorubicin, MMAE, doxorubicin hydrochloride, saporin and siRNA) to different tumor models <i>in vivo</i>. We also prepared robust nanoparticles based on polytyrosine, in which the existence of pi-pi stacking facilitates high and stable loading of lipophilic anthraquinone anticancer agents like doxorubicin and docetaxel. cRGD-functionalized nanoparticulate doxorubicin exhibited over 5 times better toleration than clinically used liposomal formulation and significantly more effective inhibition of HCT-116 colorectal tumor than the non-targeted counterpart. These polypeptide-based nanovehicles are robust and highly efficient, which renders them interesting for further clinical studies.

Robust polypeptide-based nanovehicles for controlled drug and gene delivery

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.